Anaptysbio, INC Schedule 13G passive stakes

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 5.0% of AnaptysBio, Inc. common stock as of June 30, 2026.

Point72 Asset Management and Steven A. Cohen have filed a Schedule 13G reporting a 0.2% beneficial ownership stake in AnaptysBio, Inc.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, disclosing beneficial ownership of 6.7% of AnaptysBio, Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in AnaptysBio Inc. following an internal realignment.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported reducing their beneficial ownership in AnaptysBio, Inc. to below the 5% threshold.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander jointly reported a 2.9% beneficial ownership stake in AnaptysBio, Inc. as of December 31, 2025.

First Light Asset Management and its principal, Mathew P. Arens, have filed an amended Schedule 13G, reporting their aggregate beneficial ownership in AnaptysBio Inc. at 3.12%.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have reported a 4.5% beneficial ownership stake in AnaptysBio, Inc. common stock.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has reported a 5.1% beneficial ownership stake in AnaptysBio, Inc.

First Light Asset Management and its managing member, Mathew P. Arens, disclose a combined beneficial ownership of 7.71% in AnaptysBio, Inc. common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed a combined beneficial ownership of 6.3% in AnaptysBio, Inc. common stock.

The Vanguard Group has reported a beneficial ownership of 5.23% in AnaptysBio Inc., holding 1,537,550 shares of common stock.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.9% in AnaptysBio Inc. as of May 30, 2025.

Point72 Asset Management, along with its affiliates and founder Steven A. Cohen, has disclosed a 7.7% beneficial ownership stake in AnaptysBio, Inc., holding 2,368,370 shares as of March 31, 2025.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a passive beneficial ownership of 5.2% in AnaptysBio, Inc.'s common stock.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a continued 6.2% beneficial ownership stake in AnaptysBio Inc. as of March 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.94% beneficial ownership stake in AnaptysBio Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in AnaptysBio Inc. as of March 31, 2025.

First Light Asset Management, LLC and its managing member, Mathew P. Arens, have jointly disclosed a beneficial ownership of 15.17% of AnaptysBio Inc.'s common stock.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, has disclosed a 5.6% beneficial ownership stake in Anaptysbio, Inc., totaling 1,691,372 shares.

Fairmount Funds Management LLC and its affiliated entities have fully divested their 6% beneficial ownership in AnaptysBio, Inc., as reported in an amended Schedule 13G filing.

Frazier Life Sciences and Healthcare funds, along with associated individuals, have filed an amended Schedule 13G/A to update their beneficial ownership of AnaptysBio, Inc. Common Stock.

Frazier Life Sciences and Healthcare funds, along with several key individuals, have filed an amended Schedule 13G/A disclosing their passive beneficial ownership in AnaptysBio, Inc. as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.4% of ANAPTYSBIO INC's common stock as of December 31, 2024.